InsidersTradesSigma
Total declarations
Company
▲ Purchases (10 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
10
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
+3.2%
Across 9 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Serafino Domenic, Chairman & CEO. Director active across 1 company, notably Venus Concept Inc.. Aggregated, 10 disclosures have been published. Breakdown: 10 buys · 0 sell. Total volume traded: €396k. History available since 14 June 2021. The latest transaction was disclosed on 30 August 2022 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations10 total
37,500 shares@ US$0.33923.2% of flowCommon SharesSEC:0001362118-22-000059:0
Ideal exit: 27 May 2023 (T+270)
65,000 shares@ US$0.757.97% mcap12.0% of flowCommon SharesSEC:0001567619-22-011520:0
Ideal exit: 14 Feb 2023 (T+270)
37,500 shares@ US$1.32227.57% mcap11.4% of flowCommon SharesSEC:0001567619-21-021397:0
Ideal exit: 28 Aug 2022 (T+270)
37,500 shares@ US$1.322211.0% of flowCommon SharesSEC:0001567619-21-021397
Ideal exit: 28 Aug 2022 (T+270)
17,000 shares@ US$1.47715.6% of flowCommon SharesSEC:0001567619-21-020824
Ideal exit: 16 Aug 2022 (T+270)
17,000 shares@ US$1.47713.82% mcap5.8% of flowCommon SharesSEC:0001567619-21-020824:0
Ideal exit: 16 Aug 2022 (T+270)
15,500 shares@ US$1.60085.5% of flowCommon SharesSEC:0001567619-21-020746
Ideal exit: 14 Aug 2022 (T+270)
15,500 shares@ US$1.60083.79% mcap5.7% of flowCommon SharesSEC:0001567619-21-020746:0
Ideal exit: 14 Aug 2022 (T+270)
40,000 shares@ US$2.456114.02% mcap21.1% of flowCommon SharesSEC:0001567619-21-012128:0
Ideal exit: 11 Mar 2022 (T+270)
40,000 shares@ US$2.456120.4% of flowCommon SharesSEC:0001567619-21-012128
Ideal exit: 11 Mar 2022 (T+270)
10 of 10 declarations
About Serafino Domenic
Domenic Serafino is the Chief Executive Officer of Venus Concept Inc. He is responsible for the strategic and operational direction of the company. His expertise in the medical device sector is an asset for developing innovative products.
